#USA #Los Angeles #cataract surgery #ZEISS #VERACITY

ZEISS Celebrates Major Milestone in Cataract Surgery

In the evolving landscape of ophthalmology, ZEISS has reached a remarkable milestone, celebrating over 2 million digitally planned cataract surgeries using its VERACITY Surgery Planner in the United States. This achievement not only highlights the efficacy of digital solutions in surgical planning but also reflects the growing trend of adopting technology in patient care.

Showcasing Innovations at ASCRS 2025

As a testament to its commitment to advancing medical technology, ZEISS will exhibit at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) conference, taking place from April 25 – 27, 2025, in Los Angeles, California. At this event, ZEISS plans to showcase its innovative solutions that have transformed cataract surgery practices, including the VERACITY Surgery Planner, a tool that has become instrumental for surgeons across the U.S.

The impressive adoption rate of the VERACITY Surgery Planner, marking over two million cases planned, underscores the significant role digital workflows play in enhancing surgical efficiency and patient outcomes. Surgeons utilizing this platform have reported saving as much as 60% of their time per eye when compared to traditional paper-based planning methods.

ZEISS's Digital Workflow: A Game Changer

According to Magnus Reibenspiess, head of the Strategic Business Unit for Ophthalmology at ZEISS Medical Technology, “The digital era continues to grow at a rapid pace. Ophthalmologists are increasingly realizing the significant benefits of using digital workflows as the backbone of their medical practices.” This statement encapsulates the paradigm shift occurring within the field, where efficiency and accuracy are paramount.

By leveraging data from modern electronic medical records and a variety of diagnostic devices, the VERACITY Surgery Planner empowers surgeons to make informed, data-driven decisions that ultimately lead to better patient outcomes. This shift towards digitalization in surgical planning represents a significant advancement in ophthalmological practices, ensuring surgeons have the tools they need to succeed.

Expanding Treatment Options

In addition to the milestone for the VERACITY Surgery Planner, ZEISS is broadening its refractive treatment portfolio. The introduction of both the ZEISS MEL 90 and VISUMAX 800 lasers in the U.S. reflects a strategic expansion aimed at better serving patients suffering from conditions like myopia, hyperopia, and mixed astigmatism. Dr. John Doane, a leading refractive surgeon, emphasized the MEL 90's potential, describing its FDA approval as a landmark moment in refractive surgery.

“The MEL 90 aims to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX 800 with its advanced capabilities,” he noted.

Collaboration and Knowledge Sharing

At ASCRS 2025, ZEISS will also feature collaboration with DORC and FCI, two subsidiaries that will showcase their advanced cataract surgical solutions. This will further illustrate ZEISS's comprehensive approach to meeting the diverse challenges faced by ophthalmic surgeons today.

The inclusion of cutting-edge tools like the DORC EVA NEXUS™ surgical system and other innovations highlight the company's commitment to providing surgeons with a well-rounded surgical portfolio. With the distribution of tools trusted in millions of surgeries, ZEISS continues to enhance the standard of care in ophthalmology.

Looking Ahead

As ZEISS prepares for ASCRS 2025, the company emphasizes its ongoing dedication to driving digital innovation in the field of ophthalmology. With a focus on improving patient care and operational efficiency, ZEISS stands at the forefront of transforming cataract surgery through the power of digital technology.

By celebrating this major achievement and promoting its latest advancements at ASCRS, ZEISS reinforces its leadership position in the ophthalmic market and its commitment to continuously evolving its offerings to meet the needs of both surgeons and patients alike.